Antibodies
11 December 2011
Micromet’s Blinatumomab Produces Durable Responses in Patients with Relapsed Diffuse Large B Cell Lymphoma Patients8 December 2011
Genentech Announces Positive Results of Pivotal Phase III Study with pertuzumab in HER2-Positive Metastatic Breast Cancer7 December 2011
Pharmathene Announces Publication of Phase I Study Results for Anthrax Anti-toxin Valortim7 December 2011
Pepscan Therapeutics Presents Protein Mimicry Platform for the Discovery of anti-GPCR Antibodies at International Antibody Conference7 December 2011
Amgen and FDA Agree to Modify Nplate (Romiplostim) Risk Evaluation and Mitigation Strategy6 December 2011
Peregrine’s Bavituximab Shows 50% Improvement in Overall Tumor Response Rate in Randomized Phase II Lung Cancer Trial5 December 2011
Two Year Results of Phase 3 Studies with EYLEA™ (aflibercept) Injection in wet AMD Show Sustained Improvement in Visual Acuity29 November 2011
Soliris(R) (eculizumab) Granted Marketing Authorization in Europe for Treatment of Patients with Atypical Hemolytic Uremic Syndrome (aHUS)28 November 2011
Micromet Initiates Global Phase 2 Trial of Blinatumomab in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia28 November 2011
Bayer and Regeneron Initiate Phase III Clinical Trial for the Treatment of Wet Age-Related Macular Degeneration in China24 November 2011
Tregalizumab (BT-061) shows efficacy in Chronic Plaque Psoriasis23 November 2011
Octapharma Reports octagam 5% and octagam 10% Global Sales Totaled 1.7 Million Grams Through October With No Thromboembolic Events22 November 2011
Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review22 November 2011
Peregrine Reports Promising 23.2 Month Median Overall Survival From Phase II Advanced Breast Cancer Trial19 November 2011
Regeneron Announces FDA Approval of EYLEA™ (Aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration18 November 2011
FDA Commissioner announces Avastin decision16 November 2011
The Lancet Publishes Results Demonstrating XGEVA® Significantly Prolonged Bone Metastasis-free Survival in Men With Prostate Cancer15 November 2011
Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union14 November 2011
ImmunoGen, Inc. Earns Milestone Payment From Amgen With IND Achievement for Second TAP Compound14 November 2011
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis11 November 2011
Longer-Term Data on Soliris Showed Significant and Sustained Benefits for Patients with aHUS10 November 2011
ABLYNX REPORTS PHASE II DATA FOR ALX-0081 IN HIGH RISK ACS PATIENTS UNDERGOING A PCI PROCEDURE10 November 2011
XOMA Expands Gevokizumab (XOMA 052) ProgramNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports